Jayanti Sinha, a member of the promoter group of Alkem Laboratories Ltd., is set to sell a 1.42% stake in the pharmaceutical company through a block deal, according to Bloomberg.
The floor price for the shares has been set at Rs 4,850 apiece, a discount of about 3% to Alkem's current market price.
As of March, Sinha holds 2.46% stake in the company.
There is a 90-day lockup on the seller as well, according to the terms of the block deal that is set to take place on Wednesday.
Q4 Perfomance
Alkem Laboratories reported a mixed fourth quarter for the financial year 2025. Consolidated revenue grew 7.1% year-on-year to Rs 3,144 crore, compared with Rs 2,936 crore a year earlier. Ebitda, however, fell 2.7% to Rs 391 crore from Rs 402 crore. Margins slipped to 12.4% from 13.7%. Net profit rose 4.2% to Rs 306 crore from Rs 294 crore. The company also announced a final dividend of Rs 8 per share.
The muted quarter prompted Jefferies to lower its price target to Rs 4,460. The brokerage retained an 'underperform' rating, pointing to concerns around execution on new initiatives.
Alkem Labs stock closed 1.96% lower at Rs 5,096.5 apiece, compared to a 0.70% decline in the benchmark Nifty 50 at close on Tuesday. It has risen 3.62% in the last 12 months and declined 11.31% on a year-to-date basis.
Nine out of the 22 analysts tracking the company have a 'buy' rating on the stock, six recommend a 'hold' and seven suggest a 'sell', according to Bloomberg data. The 12-month analysts' consensus target price on the stock is Rs 5,130.4, implying a upside of 2.7%.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
